Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CARRECA, Ignazio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.002
EU - Europa 1.121
AS - Asia 227
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 3.355
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.998
IT - Italia 273
UA - Ucraina 222
CN - Cina 179
DE - Germania 140
FI - Finlandia 112
IE - Irlanda 66
GB - Regno Unito 64
RU - Federazione Russa 49
FR - Francia 47
SE - Svezia 47
PL - Polonia 42
RO - Romania 23
BE - Belgio 14
KR - Corea 14
IN - India 13
NL - Olanda 7
CH - Svizzera 4
GR - Grecia 4
TR - Turchia 4
CA - Canada 3
CZ - Repubblica Ceca 3
IR - Iran 3
AU - Australia 2
ES - Italia 2
IQ - Iraq 2
MY - Malesia 2
UZ - Uzbekistan 2
BG - Bulgaria 1
BR - Brasile 1
EU - Europa 1
HK - Hong Kong 1
HR - Croazia 1
ID - Indonesia 1
JP - Giappone 1
KZ - Kazakistan 1
LB - Libano 1
MX - Messico 1
NZ - Nuova Zelanda 1
OM - Oman 1
TW - Taiwan 1
VN - Vietnam 1
Totale 3.355
Salva come PNG Salva come JPEG
Città #
Fairfield 252
Ashburn 190
Chandler 168
Woodbridge 154
Wilmington 132
Ann Arbor 117
Jacksonville 116
Houston 104
Seattle 98
Cambridge 80
Dublin 66
Medford 61
Des Moines 52
Nanjing 50
Palermo 46
Kraków 40
Princeton 39
Altamura 37
Tulsa 34
Boardman 32
Dearborn 25
Ludwigshafen am Rhein 22
Lawrence 21
Beijing 19
Nanchang 17
San Diego 17
Shenyang 16
Milan 15
Saint Petersburg 13
Brussels 12
Changsha 12
Seongnam 12
Verona 10
Hebei 9
London 9
Tianjin 8
Jiaxing 7
New York 6
San Mateo 6
Auburn Hills 5
Guangzhou 5
Taizhou 5
Düsseldorf 4
Munich 4
Ningbo 4
Nürnberg 4
Rome 4
San Francisco 4
Bolzano 3
Chicago 3
Hefei 3
Jinan 3
Kumar 3
Kunming 3
Moscow 3
Sunderland 3
Antwerp 2
Brisighella 2
Busto Arsizio 2
Calenzano 2
Changchun 2
Chengdu 2
Collesano 2
Frankfurt Am Main 2
Hangzhou 2
Ispica 2
Izmir 2
Messina 2
Norwalk 2
Nuremberg 2
Prague 2
San Pietro a Maida 2
West Jordan 2
Zhengzhou 2
Acton 1
Agrigento 1
Albolote 1
Andria 1
Bagneux 1
Bobigny 1
Boston 1
Buffalo 1
Calvisano 1
Capelle 1
Central District 1
Chiswick 1
Clearwater 1
Cleveland 1
Cliffside Park 1
Cormeilles-en-Parisis 1
Costa Mesa 1
Crotone 1
Davison 1
Dokuz 1
Dong Ket 1
Falls Church 1
Florence 1
Frankfurt am Main 1
Genoa 1
Groningen 1
Totale 2.249
Salva come PNG Salva come JPEG
Nome #
Founder mutations in BRCA1 and BRCA2 genes 188
Alla ricerca della sicurezza e della qualità: il modello di miglioramento dell’Oncologia nel Policlinico Universitario di Palermo 182
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy 182
Tailored vinorelbine-capecitabine treatment in elderly metastatic breast cancer patients. A SICOG phase II study 163
Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Colorectal Carcinoma 158
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 144
A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers 142
Reticulocytes can represent an early indicator of erythropoietic response to Darbepoetin alfa in the anemia by chemotherapy 120
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. 118
Cancer in the older person 115
Cancer chemotherapy in the older cancer patient 114
Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Prognosis in Extensive Disease Small-Cell Lung Cancer A SICOG Phase II Study 95
Temozolomide (TMZ) in radio-chemotherapy combined schedule for treatment of newly-diagnosed high-grade gliomas (HGG) 95
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 95
1. Uncommon Unresectable Advanced Ulcerative Scirrhous Carcinoma of the Nipple Destroying skin, Chest, Muscles and Ribs. Complete Remission (CR) After Epidoxorubicin (EDOX) + Gemcitabine (GEM) Weekly Administration - A Case Report 87
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 82
Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people. 81
Neoadjuvant oxaliplatin (OXA), raltitrexed (TOM), 5-fluorouracil (FU) and folinic acid (FA) + radiotherapy followed by optimal surgery in locally advanced rectal cancer (LARC) 77
Weekly cisplatin-epirubicin-paclitaxel vs. dose-dense cisplatin-epirubicin-vinorelbine in locally advanced breast cancer: Interim analysis of the SICOG 0302 phase III trial. 76
EMATOPOIESI E INVECCHIAMENTO 70
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 68
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 61
VEGF and Chromogranin A (CgA): Possible new predictive factors in management of advanced prostatic cancer (APC) in elderly patients 60
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 60
Myelotoxicity from cytostatic treatment, an important risk factor in the management of neoplasias in the elderly 60
Sorafenib (SFB) low dose in octogenarians with advanced or inoperable (a/i) HCC: Toxicity and efficacy evaluation. 59
Metronomic (M), capecitabine (C), and oxaliplatin (O) plus bevacizumab (B) as treatment of advanced colorectal cancer (ACRC) in very elderly people (M-COB): Efficacy and safety (E&S) evaluation—A 2-year monitoring 57
Antiangiogenic scheduling of lower dose chemotherapy in elderly patients with advanced colorectal cancer 56
VEGF values as a predictive factor of treatment efficiency in elderly women with advanced breast cancer 55
Antiangiogenic effects, safety and feasibility of two different capecitabine/Oxaliplatin-based schedules in elderly colorectal cancer patients 55
FULVESTRANT AND CAPECITABINE IN ELDERLY ADVANCED BREAST CANCER PATIENTS: THE PROPOSAL FOR AN EFFECTIVE AND SAFE COMBINED TREATMENT SCHEDULE. 55
SAFETY AND EFFICACY OF INHALED IL-2 THERAPY IN PRE-TREATED BREAST CANCER ELDERLY PATIENTS WITH PULMONARY METASTASES. 52
Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety 52
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 51
Non-Pegylated Liposomal Doxorubicin/Cyclophosphamide-based schedule As Antiangiogenic Treatment In Elderly Women With Advanced Breast Cancer 50
Oncogeriatry: Communication, sharing, coordination of an emerging reality. The IIIrd Official Meeting of the AIOM Working Group on Oncogeriatry 49
Capecitabine (XEL) and oxaliplatin (OX) in combination with bevacizumab (BEV) in the management of elderly patients with advanced colorectal cancer (ACRC): Preliminary outcomes on safety and efficacy. 46
VEGF levels could affect outcomes in elderly breast cancer women 45
Sorafenib (SFB) treated elderly patients (E) with hepatocellular carcinoma (HCC): Chromogranine A (CGA) plus vascular endothelial growth factor (VEGF) as predicting factors (PF) of treatment outcome. 42
Sex and Gender in Ageing and Longevity: Highlights from an International Course 11
Totale 3.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.240
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019107 0 0 0 0 0 0 0 0 0 0 55 52
2019/2020759 109 18 44 53 88 108 94 45 89 35 34 42
2020/2021540 15 87 38 51 47 5 48 24 51 61 43 70
2021/2022376 20 95 7 9 9 17 14 17 47 51 22 68
2022/2023531 71 93 0 38 86 79 45 37 51 1 24 6
2023/2024216 13 39 9 10 17 27 26 54 10 6 5 0
Totale 3.428